MedTrace Logo

Swiss Dermatology Network of Targeted Therapies (SDNTT)

NCT01706692 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1121

Last updated 2024-11-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy.

The registry will also evaluate safety clinical outcomes and health related quality of life.

Conditions

Interventions

BIOLOGICAL

Adalimumab

all dosages, frequencies and durations prescribed

BIOLOGICAL

Etanercept

all dosages, frequencies and durations prescribed

BIOLOGICAL

Infliximab

all dosages, frequencies and durations prescribed

BIOLOGICAL

Ustekinumab

all dosages, frequencies and durations prescribed

DRUG

Cyclosporine A

all dosages, frequencies and durations prescribed

DRUG

Fumaric acids

all dosages, frequencies and durations prescribed

DRUG

Methotrexate

all dosages, frequencies and durations prescribed

DRUG

Other anti-psoriatic systemic treatments

all dosages, frequencies and durations prescribed

Sponsors & Collaborators

  • Swiss Dermatology Network for Targeted Therapies

    lead OTHER

Principal Investigators

  • Alexander Navarini, Prof Dr med · Swiss Society of Dermatology and Venereology (SSDV)

  • Julia-Tatjana Maul, PD Dr med · Swiss Society of Dermatology and Venereology (SSDV)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2032-03-15
Completion
2032-03-15

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01706692 on ClinicalTrials.gov